

CURRICULUM VITAE

DANIEL F. CONNOR, M.D.

BUSINESS ADDRESS: Department of Psychiatry
MC 1410
University of Connecticut Health Center
263 Farmington Avenue
Farmington, CT 06030-1410
Telephone: 860.679.8348
Fax: 860.679.1296
Email: connor@psychiatry.uhc.edu

EDUCATION:

7/1978-6/1982 M.D. Northwestern University Medical
School, Chicago, Illinois

9/1972-5/1976 B.A. Columbia University, New York, New
York
Psychology Research Externship, Rockefeller
University, New York, New York: Mapping of Rat
CNS Serotonin Pathways with R. Waldbillig, Ph.D.

POSTGRADUATE TRAINING:

7/1985-6/1987 Fellow in Child Psychiatry, New England
Medical Center Hospitals and Tufts University School
of Medicine, Boston, Massachusetts

-Child Psychiatry Outpatient Clinics:

Two years

-Pediatric Psychopharmacology Clinic

(B. Coffey, M.D.): Two years

-Infant/Toddler Clinics: One year

-Forensic and Sexual Abuse Clinics:

Six months

-Day Hospital: Two years

-Inpatient and Consultation/Liaison Child
Psychiatry: One year

7/1983-6/1985 Resident in Adult Psychiatry, New England Medical
Center Hospitals and Tufts University School of
Medicine, Boston, Massachusetts

-Outpatient Clinics: Two years
 -Diagnostic Evaluation Clinic
 -Psychotherapy Clinic
 -Psychopharmacology Clinic
 -Inpatient and Consultation/Liaison
 Psychiatry: Two years

7/1982-6/1983 Intern in Internal Medicine and Psychiatry, New England Medical Center Hospitals and Tufts University School of Medicine, Boston, Massachusetts.

WORK EXPERIENCE:

12/2008-present	Faculty, Connecticut Children's Medical Center, Hartford, CT
7/2008-present	Consulting Faculty, Riverview Hospital for Children and Youth, Middletown, CT
10/2006-present	Program and Training Director, University of Connecticut Medical School Child & Adolescent Psychiatry Residency, Farmington, CT
5/2006-present	Professor of Psychiatry, University of Connecticut Health Center and School of Medicine, Farmington, CT
10/2005-present	Lockean Distinguished Chair in Mental Health Education, Research, and Clinical Improvement, Department of Psychiatry, University of Connecticut Health Center and School of Medicine, Farmington, CT
10/2005-present	Division Chief of Child & Adolescent Psychiatry, Department of Psychiatry, University of Connecticut Health Center and School of Medicine, Farmington, CT
10/2005-1/2006	Adjunct Professor of Pediatrics, University of Massachusetts Medical School, Worcester, MA
7/2003-9/2005	Professor of Psychiatry and Pediatrics, Departments of Psychiatry and Pediatrics, University of Massachusetts Medical School, Worcester, MA
7/2002-9/2005	Co-Director: Research in Child and Adolescent Psychiatry, University of Massachusetts Medical School

- 7/2002-9/2005 Director: Ambulatory Child and Adolescent Psychiatry, Department of Psychiatry, University of Massachusetts Medical School
- 1/1996-9/2005 Psychopharmacology Clinical Trials Program in Child and Adolescent Psychiatry, University of Massachusetts Medical School
- 7/1997-6/2003 Associate Professor of Psychiatry, Department of Psychiatry, University of Massachusetts Medical School
- 7/1996-9/2005 Program in Neuropsychiatric Sciences, University of Massachusetts Medical School
- 7/1996-1/2002 Devereux National Medical Advisory Board, The Devereux Foundation, Villanova, PA
- 7/1994-9/2005 Director, Pediatric Psychopharmacology, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA
- 7/1990-6/1997 Assistant Professor of Psychiatry, Department of Psychiatry, University of Massachusetts Medical Center
- 7/1989-6/1990 Director: Child & Adolescent Psychiatry, Wing Memorial Hospital, Palmer, MA, and Assistant Professor of Psychiatry, Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA
- 7/1987-6/1989 Assistant Professor of Psychiatry, Department of Psychiatry, University of Massachusetts Medical School, Director, Acute Adolescent Inpatient Psychiatry, Westboro, MA

CLINICAL AND EDUCATIONAL ACTIVITIES AT THE UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE:

10/2006-present

Founding Program Director and first Training Director of the University of Connecticut Medical School Child & Adolescent Residency Program. Accredited by the ACGME in October 2006, the program is the first accredited training program in child and adolescent psychiatry at the University of Connecticut Health Center and Medical School.

9/30/2005-present

Founding Program Director and first Division Chief of the new Division of Child & Adolescent Psychiatry at the University of Connecticut Medical School and Health Care.

The new Division serves to train University of Connecticut medical students, psychiatry residents, and allied mental health disciplines in the field of child & adolescent psychiatry, and provides clinical expertise and research with a focus on public sector child and adolescent psychiatry for the state of Connecticut.

7/1/2006-present

Founding, organization, and direction of a new ambulatory child & adolescent psychiatry clinic in the UCHC Department of Psychiatry at University Health Partners, West Hartford for the University of Connecticut School of Medicine. Previous to the clinic opening UCHC had no resource in outpatient child and adolescent psychiatry. This clinic is a primary teaching site of general psychiatry, psychology, social work, and child and adolescent psychiatry at UCHC.

1/24/06-present

Consultant to Riverview Hospital for Children. The Connecticut Department of Children and Families (DCF) supports this consultation with the aim of providing the hospital with outside expert consultants to make recommendations in the areas of safety, patient aggression, pediatric psychopharmacology, and trauma-based services with an overall goal of enhancing clinical care for children and adolescents at Riverview Hospital (RVH). A UCHC Department of Psychiatry consulting team (Drs Albert, Ford, Steinberg, Franks, and Connor) provides critical incident debriefing, trauma-support services, clinical service consultation, training, and education to staff at Riverview over 15 months. The consulting program is funded at \$276,670 per year by DCF. Previous to this consult, UCHC psychiatry was not present at Riverview Hospital that historically was staffed by psychiatry faculty from Yale School of Medicine Department of Psychiatry. RVH is a primary teaching site in the new UCHC 4th year medical student elective in child & adolescent psychiatry.

1/24/2006 - present

Pediatric Psychopharmacology Consult Services to Riverview Hospital for Children. The Connecticut Department of Children and Families (DCF) supports this consultation with the aim of providing the hospital with outside expert consultation in pediatric psychopharmacology. At the invitation of DCF, Dr. Connor provides pediatric psychopharmacology consultation to the RVH child psychiatry staff on a weekly basis. The consulting program is funded at \$20,000 per year by DCF.

7/1/2006 – present

Child & Adolescent Psychiatry Services to the Department of Corrections at Manson Youth Corrections. Founding director of a new forensic child psychiatry - teaching clinic located within the Manson Youth Corrections building in Cheshire, CT. Dr. Connor and two UCHC psychiatry residents provide pediatric psychiatry evaluation and ongoing pediatric psychopharmacology treatment to incarcerated adolescents under a contract with Connecticut Dept. of Corrections. This clinic serves as a new primary teaching site in adolescent corrections psychiatry for UCHC general psychiatry residents, child psychiatry fellows, and 4th year medical students completing and elective in child and adolescent psychiatry.

CLINICAL ACTIVITIES AT THE UNIVERSITY OF MASSACHUSETTS SCHOOL OF MEDICINE:

1/2003-9/2005

Operations Director: Massachusetts Child Psychiatry Access Project (MCPAP). This is an innovative Massachusetts State supported, capitated, child psychiatry project whose purpose is to enhance the access of pediatric patients referred by primary care physicians to child psychiatrists for psychiatric evaluation and brief stabilization. Other aims of the MCPAP project include educating primary care physicians about mental health diagnostic and treatment issues and providing consultation in real-time via a pager for their mental health questions. The program at the University of Massachusetts Medical School Division of Child and Adolescent Psychiatry is funded at \$485,000 per year by the state of Massachusetts. One FTE child psychiatry position and a mental health team of a care coordinator and a social worker support child and adolescent mental health referrals from over 100 primary care physicians, pediatric neurologists, and pediatric sub-specialists in the Central Massachusetts area.

7/1990-9/2005

Pediatric Psychopharmacology Clinic: Founder and Director, UMass/Memorial Health Care and the Department of Psychiatry/Division of Child and Adolescent Psychiatry, University of Massachusetts Medical School. The clinic evaluates children 6 to 18 years old with behavioral, emotional, cognitive, and developmental disturbances for possible psychopharmacological intervention. The clinic utilizes a LEAD (longitudinal, expert, all data) multidisciplinary team format including structured psychiatric diagnostic interviewing of parents and guided interviews with children. Staff includes child and adolescent psychiatry and a pediatric mental health clinical nurse specialist. It is a major training site for first year Child Psychiatry Fellows and consults closely with the Department of Pediatrics, the Division of Pediatric Neurology, Family and Community Medicine, and community referral sources.

7/1990-1/2003

Consulting Psychiatrist: The Devereux Foundation, Rutland, MA (1990-2003). This is a private, not for profit residential school serving 5 to 22 year old youth with serious emotional disturbances. Responsibilities include direct psychopharmacology intervention and follow-up, multidisciplinary team meeting participation, medico-legal consultation around forensic issues, and school consultation to teachers.

7/1990-6/1997

Community Consultation: Consulting Psychiatrist: Worcester Youth Guidance Center, Worcester, MA. This is a public sector child and family guidance center. The population is generally multicultural and poor with severe problems. Responsibilities include direct psychopharmacology intervention, multidisciplinary team participation, follow-up and evaluation, crisis evaluation, consultation to staff, and training for staff in case formulation, treatment goal setting, evaluation, and psychopharmacology.

7/1989-6/1990 Child and Adolescent Psychiatrist, Wing
Memorial Hospital, Palmer, Massachusetts

Consulting Psychiatrist, Worcester Youth
Guidance Center, Worcester, MA

Assistant Professor of Psychiatry, Division of Child
Psychiatry, University of Massachusetts Medical Center
Voluntary Faculty

Supervision of Child Psychiatry Fellows

7/1987-6/1989 Assistant Professor of Psychiatry, Division of Child
Psychiatry, University of Massachusetts Medical Center

Medical Director: Acute Adolescent Inpatient Unit, Westboro
State Hospital

Director, Pediatric Psychopharmacology Clinic, UMMC

Supervision of Child Psychiatry Fellows

**TEACHING EXPERIENCE UNIVERSITY OF CONNECTICUT SCHOOL OF
MEDICINE:**

7/2006 to Present: Child & Adolescent Psychiatry Core Curriculum, University of Connecticut Medical School: Founding Director, development, lectures, and coordination. Taught to medical students, psychiatry residents, child & adolescent psychiatry fellows, psychology graduate students, advanced-practice nursing students, and social work students in the UCHC Psychiatry Department.

9/2005 to Present: Pediatric Psychopharmacology Core Curriculum: Development, lectures, and coordination. This curriculum is comprised of didactic lectures and ongoing case supervision teaching the present standard of care in pediatric psychopharmacology. Taught to Medical Students, Child Psychiatry Fellows, General Psychiatry Residents, Pediatric Residents, and Psychology Interns at UCHC Department of Psychiatry.

9/2005 to Present: Ongoing case supervision of Child Psychiatry Fellows and General Psychiatry Residents, Clinical Psychologists, and APRNs in Pediatric Psychopharmacology and in Child & Adolescent Psychiatry at the University of Connecticut School of Medicine.

7/2006 to Present: Mentoring of UCHC psychiatry residents in relation to their career goals and aspirations.

7/2006 to Present: Mentoring of UCHC psychiatry junior faculty in relation to their career goals and aspirations, and plans for academic promotion.

TEACHING EXPERIENCE UNIVERSITY OF MASSACHUSETTS SCHOOL OF MEDICINE:

7/2000 to 6/2005: Pediatric/Child Psychiatry Joint Case Conference: Supported by unrestricted educational grants from the pharmaceutical industry to Dr. Connor, this conference includes child psychiatry fellows, medical students in pediatrics, pediatrics residents, and staff from Pediatrics, Psychology, Child and Adolescent Psychiatry, and Pediatric Neurology. Complicated clinical cases from primary care and neurology with a mental health component are presented and discussed. The goals of the case conference are to enhance the psychiatric education of primary care trainees, facilitate communication across academic departments, and enhance the clinical care of complicated pediatric patients. Departments of Pediatrics and Psychiatry, University of Massachusetts Medical School.

7/1990 to 7/2005: School Consultation Core Curriculum: Development and coordination. This curriculum is designed to help Child Psychiatry Fellows learn about, experience, and obtain supervision in consultation to teachers in a residential school setting. Done at the Devereux Foundation, Rutland, MA and the Department of Psychiatry, University of Massachusetts Medical School.

7/1990 to 6/1998: Case Evaluation, Formulation, and Treatment Goal Planning: Co-developer and coordinator of a core curriculum and manual designed to teach allied mental health disciplines principles of child and adolescent mental health evaluation, case formulation, and focused treatment planning utilizing a combination of four guided interviews combined with rating scales that yield dimensional data. Done at Worcester Youth Guidance Center and the Department of Psychiatry University of Massachusetts Medical School.

UNIVERSITY OF CONNECTICUT MEDICAL SCHOOL TEACHING LECTURES AND SEMINARS

MEDICAL STUDENT TEACHING

- 8/2006 to Present: Development, initiation, and founding course director for a new 4th year medical student elective in child and adolescent psychiatry at the University of Connecticut School of Medicine. Medical students interested in child psychiatry rotate through a one-month elective with outpatient, inpatient, and juvenile corrections clinical experience.
- 5/2006 To Present: Mechanisms of Disease Course, Child and Adolescent Psychiatry: 2nd year medical students; University of Connecticut School of Medicine, Farmington, CT (May 4)
- 2006 to Present: Lectures to Third Year Medical Students during psychiatry clerkship: Child and Adolescent Psychiatry; ADHD and Depression

GRADUATE MEDICAL EDUCATION

- 1/2006: Systems of Care in Psychiatry: Taught to UCHC psychiatry residents.
- 9/2006: Drill Down Seminars in Child Psychiatry (depression, bipolar disorders, psychotic disorders, personality disorders): Taught to UCHC psychiatry residents (9/06 to present).
- 1/2008 Graduate School: Neurobiology of Disease: ADHD in Children & Adolescents

UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL TEACHING
LECTURES AND SEMINARS

1. Depression in children and adolescents: Medical students UMass Medical School
2. Decision-making in pediatric psychopharmacology: General Psychiatry Residents and Child & Adolescent Psychiatry Fellows, UMass
3. Pediatric psychopharmacology of aggression and conduct disorder: General Psychiatry Residents and Child & Adolescent Psychiatry Fellows
4. SSRIs and other antidepressants: Pediatric Residents and Child Neurology Fellows
5. Medication management of ADHD in children and adolescents: Pediatric Residents and Child Neurology Fellows
6. Medication management of adult ADHD: Community Medicine staff
7. How to critically assess the child psychiatry scientific literature: Child & Adolescent Psychiatry Fellows
8. How to read a journal article: Child & Adolescent Psychiatry Fellows
9. The case formulation and its role in child and adolescent psychiatry: Psychiatry Residents and Child & Adolescent Psychiatry Fellows
10. The SSRI and suicide controversy: Adolescent Medicine, UMass
11. Stimulants and Clonidine: UMass Psychiatry Residents and Child & Adolescent Psychiatry Fellows
12. Medications for juvenile aggression and conduct problems: UMass Psychiatry Residents and Child & Adolescent Psychiatry Fellows
13. Pediatric Psychopharmacology Review: UMass Law and Psychiatry Program, Court Clinicians
14. Oppositional Defiant Disorder: Child & Adolescent Psychiatry Fellows
15. Assessment in Child & Adolescent Psychiatry: Child and Adolescent Psychiatry Fellows, Department of Psychiatry, University of Massachusetts Medical School.
16. Adaptive and Maladaptive Aggression in Psychiatrically Referred Children and Adolescents: Child and Adolescent Psychiatry Fellows, Department of Psychiatry, University of Massachusetts Medical School.
17. Psychopharmacology: Graduate Students in Neurobiology, Department of Neurosciences, University of Massachusetts Graduate School, Worcester, MA.
18. Pediatric Psychopharmacology: Brudnick Neuropsychiatric Institute, Worcester, MA.

COMMUNITY AND CME EDUCATION

1. Depression in Youth, Teens, and Young Adults. University of Connecticut Health Center Discovery Series, Depression Across the Generations, Farmington, CT (10/2006).
2. 9/2004: CME Course: The Heavy Burden of ADHD in Adults: New Understanding of the Neurobiology, Diagnosis, and Treatment Options. Veritas Institute and Shire Pharmaceuticals.
3. 9/2005: CME Course: The Adolescent ADHD Patient: Effective Management With or Without Oppositional Defiant Disorder. Veritas Institute and Shire Pharmaceuticals.
4. 9/2006 to present: CME Course: University of Connecticut Health Center Division of Child & Adolescent Psychiatry Monthly Collaborative ADHD Case Conference Series with the University of Connecticut Department of Pediatrics at CCMC.

ADMINISTRATIVE EXPERIENCE AT UCHC DEPARTMENT OF PSYCHIATRY AND UNIVERSITY OF CONNECTICUT MEDICAL SCHOOL

- Child & Adolescent Psychiatry Division Director, University of Connecticut Health Center and the University of Connecticut School of Medicine
- Child & Adolescent Psychiatry Residency Training Director, University of Connecticut Health Center and the University of Connecticut School of Medicine
- Department of Psychiatry, Executive Committee, University of Connecticut Health Center
- Department of Psychiatry, Senior Appointments and Promotions Committee, University of Connecticut School of Medicine
- Department of Psychiatry, Residency Training Committee, University of Connecticut Health Center

ADMINISTRATIVE EXPERIENCE AT THE UNIVERSITY OF MASSACHUSETTS DEPARTMENT OF PSYCHIATRY AND MEDICAL SCHOOL

- Child and Adolescent Psychiatry Fellowship Training and Selection Committee, University of Massachusetts Medical School
- Research Administration in Child and Adolescent Psychiatry, University of Massachusetts Medical School
- Pediatric Psychopharmacology Service Administration, University of Massachusetts/Memorial Health Care
- Ambulatory Child and Adolescent Service Administration, University of Massachusetts/Memorial Health Care
- Pharmacy and Therapeutics Committee, University of Massachusetts/Memorial Health Care
- Child and Adolescent Psychiatry Administration Operations and Steering Committee, University of Massachusetts Medical School

- Massachusetts Child Psychiatry Access Project (MCPAP): Operations Administration, Department of Psychiatry, University of Massachusetts/Memorial Health Care
- Research Committee: Department of Psychiatry, University of Massachusetts Medical School

NATIONAL and INTERNATIONAL PRESENTATIONS:

- 1995 New York Academy of Sciences: Understanding Aggressive Behavior in Children. Rockefeller University, NY, NY: Pediatric Psychopharmacology of Aggression.
- 1995 47th Institute on Psychiatric Services: Boston, MA:
 - Pediatric Psychopharmacology of Aggression
 - Stimulants in ADHD
- 1996 43rd Annual Meeting American Academy of Child and Adolescent Psychiatry, Philadelphia, PA: Child and Adolescent Aggression and Comorbidity
- 1997 American Association on Mental Retardation: Virginia Beach, VA: Pediatric Psychopharmacology and Developmental Delay
- 1998 American Psychiatric Association: Toronto, Canada: Stimulants in Child and Adolescent Psychopharmacology
- 1999 American Psychiatric Association: Washington, DC: Stimulants in Child and Adolescent Psychopharmacology
- 2002 Shire Pharmaceuticals: Tampa, Florida: A Phase III Study of Adderall XR in Children and Adolescents with Oppositional Defiant Disorder (ODD)
- 2002 International Society for Research on Aggression, 15th Annual Meeting, Montreal (Quebec): Proactive and Reactive Aggression in Referred Children and Adolescents
- 2003 New York Academy of Sciences, The Rockefeller University, New York, New York, Roots of Mental Illness in Children: Aggressive Behavior in Abused Children
- 2003 National Capital Symposium on Impulsive Aggression in Children, Howard University Medical School, Washington, DC: Gender Differences in Proactive and Reactive Aggression
- 2003 American Academy of Child and Adolescent Psychiatry, 50th Annual Meeting, Miami, Florida: Aggression in Children and Adolescents
- 2004 Stanford University School of Medicine, Palo Alto, CA: The 7th Annual Stanford Symposium on Developmental Approaches to Psychopathology:
 - Diagnosing and Treating Maladaptive Aggression and Related Psychopathology
 - Stimulants and Related Compounds
- 2004 9th Annual Shire Pharmaceuticals ADHD Expert Advisory Board, Phoenix, Arizona: A Phase III, Multicenter, Randomized, Placebo-Controlled Trial of Adderall XR in Children and Adolescents with Oppositional Defiant Disorder
- 2004 American Academy of Child and Adolescent Psychiatry, 51st Annual Meeting, Washington, DC: Symposium on Juvenile Impulsivity and Aggression:

- Basic Neuroscience, Development, Diagnosis, and Treatment: Juvenile Maladaptive Aggression and Treatment.
- 2004 Eastern Medicaid Pharmacy Administrators Association Annual Meeting, Hersey, PA: Pediatric Psychopharmacology. What is the Evidence Base?
 - 2005 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada: Clinical Case Conference on Getting Aggressive in the Treatment of Aggression: Proactive/Reactive Aggression in Abused Children.
 - 2005 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada: Symposium: Two Subtypes of Aggression: Neuroscience, Taxonomy, Measurement, and Treatment: Treatment of Maladaptive Aggression.
 - 2006 Cephalon, Inc., Scientific Medical Liaison Annual Meeting, Miami, Florida, ADHD and Comorbidity.
 - 2006 Shire Pharmaceuticals, Medical Scientific Liaison Annual Meeting, Minneapolis, Minnesota, Oppositional Defiant Disorder in Children.
 - 2006 24th Congress of Psychiatry & Neurology of Infancy and Adolescence, Vina del Mar, Chile:
 - Treatment of Maladaptive Aggression in Children & Adolescents
 - Conduct Disorder and Comorbidity
 - 2006 53rd Annual Meeting of the American Academy of Child & Adolescent Psychiatry, San Diego, CA: Translational Research, Atypical Antipsychotics, and the Behavioral Pharmacology of Aggression, Daniel F. Connor, M.D. Chair:
 - Quetiapine in the Treatment of Adolescent Conduct Disorder
 - 2007 160th Annual Meeting of the American Psychiatric Association, San Diego, CA: The “hidden” diagnosis in psychiatry: Implications for training, clinical care, and outcomes
 - 2007 54th Annual Meeting of the American Academy of Child & Adolescent Psychiatry, Boston, MA: Emotion dysregulation and sensory reactivity: early childhood diagnoses and parenting (Alice S. Carter, PhD, University of Massachusetts at Boston, Chair)
 - Discussant: Implications for Child Psychiatry, Daniel F. Connor, M.D.
 - 2008 Shire Pharmaceuticals Mechanism of Action Guanfacine Extended Release ADHD Advisory Board Meeting
 - Houston, Tx. 5/14/2008
 - Orlando, Fl. 5/21/2008
 - 2008 University of Buffalo Department of Psychiatry Grand Rounds:
 - Targeted Child Psychiatric Services
 - 2008 University of Buffalo Division of Child and Adolescent Psychiatry:
 - A Rational Approach to the Problem of Aggression in Referred Children and Adolescents
 - 2008 Shire Pharmaceuticals ADHD Expert Consortium: Applying the Science to Clinical Practice. Dallas, TX 11/21/08 to 11/23/08
 - 2009 American Academy of Child & Adolescent Psychiatry; 34th Annual Review Course in CAP and Training Session for the Oral Exams: Oppositional Defiant Disorder and Conduct Disorder. Boston MA 4/29/09-5/2/09

- 2009 Shire Pharmaceuticals National Guanfacine XR Advisory Board; San Francisco, CA: Mechanism of Action.
- 2009 ADHD and Emotional Dysregulation. What the clinician sees: ADHD, comorbidity, emotional symptoms, and behavioral dysregulation. Invited presentation Shire Pharmaceuticals, Hollywood, Florida 6/27/2009.

REGIONAL PRESENTATIONS:

- 1988 Grand Rounds: Tufts New England Medical Center, Department of Psychiatry: Adolescents on an Inpatient Psychiatry Unit.
- 1991 Grand Rounds: University of Massachusetts Medical Center, Department of Psychiatry: Tricyclic Antidepressants in Pediatric Psychopharmacology: Indications and Use.
- 1994 New England Council for Child and Adolescent Psychiatry: Boston, MA: Pediatric Psychopharmacology and Aggression.
- 1995 Massachusetts Pediatric Society: Boston, MA: Attention Deficit Hyperactivity Disorder
- 1995 New England Council for Child and Adolescent Psychiatry: Boston, MA: Clinical Evaluation of Complex Cases
- 1996 New England Council for Child and Adolescent Psychiatry: Boston, MA: Comorbidity in ADHD
- 1998 Baystate Medical Center, Department of Psychiatry: Springfield, MA: A Clinical Approach to Aggression. What We Know and What We Don't Know
- 1998 Worcester State College, Science Lecture Series: Worcester, MA: Psychopharmacology and Neuropsychiatric Disorders in Children
- 1999 Holy Cross College, Devereux Legacy of Caring Conference: Worcester, MA: Aggression in Seriously Emotionally Disturbed Youth
- 1999 Northeastern University, Department of Psychology: Boston, MA: Aggression in Children and Adolescents
- 2000 Blue Cross/Blue Shield WellChild Foundation: Boston, MA: Too Young for ADHD?
- 2000 Grand Rounds: University of Massachusetts Memorial Health Care Department of Pediatrics: What's New in ADHD?
- 2001 Grand Rounds: University of Massachusetts Memorial Health Care Department of Psychiatry: The Impact of Aggression on the Clinical Care of SED Children and Adolescents
- 2001 Massachusetts Department of Social Services/Commonworks: Working with Aggressive/Assaultive Youth in Residential Treatment
- 2001 New England Council for Child and Adolescent Psychiatry: Boston, MA: Depression in Children and Adolescents
- 2002 Department of Psychiatry, University of Massachusetts Medical School: Worcester, MA: Advances in the Treatment of ADHD in Children and Adults
- 2002 Devereux Institute for Clinical Training and Research, Villanova, PA: The Devereux Early Developmental Stress and Aggression Project

- 2002 The University of Massachusetts Medical School Department of Pediatrics 25th Annual Office Pediatrics Symposium, Worcester, MA: Psychopharmacology: Treating ADHD in Your Office
- 2002 The 8th New England Joint Conference on Specific Learning Disabilities, Marlborough, MA: Medication Management of Childhood ADHD and Co-morbid Disorders
- 2002 Northeastern Massachusetts Law Enforcement Council School Threat Assessment Response System, Andover, MA: Risk Factors for Aggression and Antisocial Behavior in Children and Adolescents
- 2002 The New England Regional Chapter Society of Adolescent Medicine, Interdisciplinary Approach to Adolescent Health, Mansfield, MA: Pediatric Psychopharmacology
- 2002 The Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA: Clinical Research for the Clinician
- 2002 The University of Connecticut School of Medicine & The Connecticut Children's Medical Center, Hartford, CT: ADHD and Pharmacology in Early Childhood
- 2003 The University of Massachusetts/Memorial Health Care, Department of Family and Community Medicine, Worcester, MA: ADHD in Community Practice
- 2003 The Institute for Living, Hartford, CT: An Update on ADHD
- 2003 The University of Massachusetts/Memorial Health Care, Department of Family and Community Medicine, Worcester, MA: Adult ADHD
- 2003 The University of Massachusetts/Memorial Health Care, Department of Pediatrics, Worcester, MA: Depression and Anxiety in Children and Adolescents
- 2004 The University of Massachusetts Medical School, Department of Psychiatry and Massachusetts Department of Mental Health, Worcester, MA: Juvenile Court Clinics Specialty Forensics Training: Pediatric Psychopharmacology
- 2004 The University of Massachusetts Medical School, Department of Medicine, Worcester, MA: Adult ADHD
- 2004 Northeast Massachusetts Law Enforcement Council: School Threat Assessment Response System: Depression and Conduct Disorder in Teenagers
- 2004 Department of Pediatrics, Baystate Health System, Springfield, MA: Practical Child and Adolescent Psychiatry: Assessment and Treatment of Childhood-Onset Mood Disorders
- 2004 Department of Pediatrics, University of Massachusetts Medical School, Worcester, MA: Symposium on Practical Pediatrics: Depression in Children and Adolescents
- 2004 Department of Pediatrics, University of Massachusetts Medical School, Annual Research Retreat: Aggression and Psychiatric Diagnosis
- 2004 Tufts Health Plan, Waltham, MA: Psychopharmacology for the General Pediatrician
- 2005 Harvard Medical School Department of Continuing Education, Boston, MA: Adolescent Self-Destruction: Aggression and Antisocial Behavior in Children and Adolescents: Research and Treatment

- 2005 Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA: Panic Disorder in Children and Adolescents.
- 2005 Department of Psychiatry, University of Connecticut Health Center, Farmington, CT: Targeted Child Psychiatric Services – A New Model of Primary Clinician-Child Psychiatry Collaborative Care in the Treatment of Early-Onset Mental Health Disorders.
- 2005 Mental Health Legal Advisors Committee, The Commonwealth of Massachusetts Supreme Judicial Court, Boston, MA: Aggression and Antisocial Behavior in Children and Adolescents.
- 2005 The New England Regional Chapter, Society of Adolescent Medicine Annual Meeting, Sturbridge, MA: Pediatric Psychopharmacology.
- 2005 Child Health and Development Institute of Connecticut, Cromwell, CT: Behavioral Health and Primary Care: Targeted Child Psychiatric Services Model.
- 2006 Riverview Hospital for Children and Youth, Middletown, CT: Conduct Disorder and Comorbidity.
- 2006 Department of Psychiatry, University of Connecticut Medical School, Farmington, CT: Maladaptive Aggression in Referred Children.
- 2006 American Health Resources, PharmED, Rocky Hill, CT: Understanding ADHD: Improving Patient Care.
- 2006 Department of Pediatrics, Connecticut Children's Medical Center, Hartford, CT: Targeted Child Psychiatric Services: A New Model of Collaborative Behavioral Health Care.
- 2006 Department of Psychiatry/Division of Child & Adolescent Psychiatry, Long Island Jewish Medical Center/Zucker-Hillside Hospital, Glen Oaks, New York: Maladaptive Aggression in Referred Children & Adolescents: Phenomenology and Treatment.
- 2007 Riverview Hospital for Children and Youth, Middletown, CT: Gender, Aggression, and Abuse in a Clinical Sample.
- 2008 Department of Psychiatry UCHC, Farmington, CT: A clinical dilemma: Recognizing and treating adult ADHD in the context of bipolar illness.
- 2008 Riverview Hospital for Children and Youth, Middletown, CT: A Rational Approach to the Problem of Aggression in Children and Adolescents: July 16, 2008.
- 2009 American Health Resources, Rocky Hill, CT: Drug Therapy Options for ADHD: Evaluating the Choices, May 27, 2009.
- 2009 Riverview Hospital for Children and Youth, Middletown, CT: Psychopharmacology of Aggression: July 15, 2009.
- 2009 Northeast Conference on ADHD, Jiminy Peak Resort, Hancock, MA:
 - Psychopharmacology for ADHD school-aged and preschool children
 - Complex ADHD
 - Psychopharmacology for ADHD teenagers and adults
- 2010 UCHC Department of Psychiatry Grand Rounds, Farmington, CT:
 - Attention Deficit Hyperactivity Disorder: Where Have Behavior and Emotion Gone?

BOOKS:

1. Connor, DF: *Aggression & Antisocial Behavior in Children and Adolescents: Research and Treatment*. New York, NY: Guilford Press, 2002 (480 pages)
 - a. Russian edition (2005).
 - b. Japanese edition (2008)
2. Connor, DF, Meltzer, BM: *Pediatric Psychopharmacology, Fast Facts*. New York, NY: WW Norton, 2006 (685 pages).

PEER-REVIEWED PUBLICATIONS:

**Corresponding Author

1. Connor, DF: Beta Blockers for Aggression: A Review of the Pediatric Experience. *Journal of Child and Adolescent Psychopharmacology* 3: 99-114, 1993
2. Connor, DF: Nadolol for Self-injury, Overactivity, Inattention, and Aggression in a Child with Pervasive Developmental Disorder. *Journal of Child and Adolescent Psychopharmacology* 4: 101-111, 1994
3. Wilens, T E, Spencer, T, Biederman, J, Wozniak, J, Connor, DF: Combined Pharmacotherapy: An Emerging Trend in Pediatric Psychopharmacology. *Journal of American Academy of Child and Adolescent Psychiatry* 34: 110-112, 1995
4. Connor DF, Benjamin, S, Ozbayrak, KR: Neuroleptic Withdrawal Dyskinesia Exacerbated by Ongoing Stimulant Treatment. *Journal of the American Academy of Child and Adolescent Psychiatry* 34: 1490-1494, 1995
5. Connor, DF, Ozbayrak, KR, Kusiak, KA, Caponi, AB, Melloni, Jr., RH: Combined Pharmacotherapy in Children and Adolescents in a Residential Treatment Center. *Journal of the American Academy of Child and Adolescent Psychiatry* 36: 248-254, 1997
6. Cantwell, D, Swanson, JM, Connor, D: Adverse Response to Clonidine. *Journal of the American Academy of Child and Adolescent Psychiatry* 36: 539-544, 1997
7. Melloni, Jr., RH, Connor, DF, Xvan Hang, PT, Harrison, RJ, Ferris CF: Anabolic-Androgenic Steroid Exposure During Adolescence Stimulates Aggressive Behavior in Golden Hamsters. *Physiology and Behavior* 61: 359-364, 1997
8. Connor, DF, Fisher, SG: An Interactional Model of Child and Adolescent Mental Health Clinical Case Formulation. *Journal of Clinical Child Psychology and Psychiatry* 2: 349-364, 1997
9. Connor, DF, Ozbayrak, KR, Benjamin, S, Ma, Y, Fletcher, KE: A Pilot Study of Nadolol for Overt Aggression in Developmentally Delayed Individuals. *Journal of the American Academy of Child and Adolescent Psychiatry* 36:826-834, 1997
10. Connor DF, Melloni, Jr. RH, Harrison RJ: Overt Categorical Aggression in Referred Children and Adolescents. *Journal of the American Academy of Child and Adolescent Psychiatry* 37:66-73, 1998
11. Connor, DF, Ozbayrak, KR, Harrison, RJ, Melloni, Jr., RH: Prevalence and Patterns of Psychotropic and Anticonvulsant Medication Use in Children and Adolescents Referred to Residential Treatment. *Journal of Child and Adolescent Psychopharmacology* 8:27-38, 1998

12. Connor DF, Posever, TA: A Brief Review of Atypical Antipsychotics in Individuals with Developmental Disabilities. *Mental Health Aspects of Developmental Disabilities* 1:93-102, 1998
13. Connor DF, Fletcher KE, Swanson, JM: A Meta-Analysis of Clonidine for Symptoms of Attention-Deficit Hyperactivity Disorder. *Journal of the American Academy of Child and Adolescent Psychiatry* 38:1551-1559, 1999
14. Connor DF, Barkley RA, Davis HT: A Pilot Study of Methylphenidate, Clonidine, or the Combination in ADHD Comorbid with Aggressive Oppositional Defiant or Conduct Disorder. *Clinical Pediatrics* 39:15-25, 2000
15. Harrison RJ, Connor DF, Nowak C, Nash K, Melloni RH: Chronic anabolic-androgenic steroid treatment during adolescence increases anterior hypothalamic vasopressin and aggression in intact hamsters. *Psychoneuroendocrinology* 25: 317-338, 2000
16. Harrison RJ, Connor DF, Nowak C, Melloni RH: Chronic low-dose cocaine treatment during adolescence facilitates aggression in hamsters. *Physiology and Behavior* 69: 555-562, 2000
17. Barkley RA, Connor DF, Kwasnik D. Challenges to determining adolescent medication response in an outpatient clinical setting: Comparing Adderall and methylphenidate for ADHD. *Journal of Attention Disorders* 4: 102-113, 2000
18. Melloni Jr. RH, Connor DF, Todtenkopf MS, DeLeon KR, Sanyal P, Harrison RJ: Repeated cocaine treatment activates flank marking in adolescent female hamsters. *Physiology & Behavior* 73: 561-570, 2001
19. Connor DF, Fletcher KE, Wood, JS: Neuroleptic-related dyskinesias in children and adolescents. *Journal of Clinical Psychiatry* 62: 967-974, 2001
20. Connor DF, Glatt SJ, Lopez ID, Jackson D, Melloni, Jr. RH: Psychopharmacology and aggression. I. A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD. *Journal of the American Academy of Child and Adolescent Psychiatry* 41:253-261, 2002
21. Connor DF: Preschool attention deficit hyperactivity disorder: A review of prevalence, diagnosis, neurobiology, and stimulant treatment. *Developmental and Behavioral Pediatrics* 23 (1S): S1-S9, 2002
22. Steingard RJ, Renshaw PF, Hennen J, Lenox M, Vakili K, Young AD, Connor DF, Au TH, Yurgelun-Todd, D: Smaller frontal lobe white matter volumes in depressed adolescents. *Biological Psychiatry* 52: 413-417, 2002
23. DeLeon KR, Grimes JM, Connor DF, Melloni, Jr. RH: Adolescent cocaine exposure and offensive aggression: involvement of serotonin neural signaling and innervation in male Syrian hamsters. *Behavioural Brain Research* 133: 211-220, 2002
24. Connor DF, Miller K, Cunningham J, Melloni, Jr. RH: What does getting better mean? Variables associated with child improvement and measurement of outcome in residential treatment. *American Journal of Orthopsychiatry*, 72(1):110-117, 2002.
25. Cunningham J, Connor DF, Miller, K, Melloni, Jr. RH: Staff survey results and characteristics that predict assault and injury to personnel working in mental health facilities. *Aggressive Behavior*, 29 (1):31-40, 2003.

26. Connor DF, McIntyre EK, Miller K, Brown C, Bluestone H, Daunais D, LeBeau S: Staff retention and turnover in a residential treatment center. *Residential Treatment for Children & Youth*, 20(3):43-53, 2003.
27. Connor DF, Edwards G, Fletcher KE, Baird J, Barkley RA, Steingard RJ: Correlates of comorbid psychopathology in children with ADHD. *Journal of the American Academy of Child and Adolescent Psychiatry*, 42 (2):193-200, 2003.
28. Connor DF, Steingard RJ, Anderson JJ, Melloni, Jr. RH: Gender differences in reactive and proactive aggression. *Child Psychiatry and Human Development*, 33(4), 279-294, 2003.
29. Connor DF, Boone RT, Steingard RJ, Lopez ID, Melloni, RH: Psychopharmacology and aggression. II. A meta-analysis of non-stimulant medication effects on overt aggression-related behaviors in youths with serious emotional and behavioral disorders. *Journal of Emotional and Behavioral Disorders* 11(3), 157-168, 2003.
30. Connor DF, Steingard RJ, Cunningham JA, Anderson JJ, Melloni, RH: Proactive and reactive aggression in referred children and adolescents. *American Journal of Orthopsychiatry* 74(2), 129-136, 2004.
31. Connor DF, Steingard RJ: New formulations of stimulants for attention-deficit/hyperactivity disorder: Therapeutic potential. *CNS Drugs* 18(14): 1011-1030, 2004.
32. Connor DF, Doerfler LA, Toscano, Jr. PF, Volungis AM, Steingard RJ: Characteristics of children and adolescents admitted to a residential treatment center. *Journal of Child and Family Studies* 13(4), 497-510, 2004.
33. Connor DF, Doerfler LA: The assessment of aggression in child and adolescent psychiatry. *Mental Fitness* (In Press, Sept. 2004).
34. Wilens TE, Haight BR, Horrigan JP, Hudziak JJ, Rosenthal NE, Connor DF, Hampton KD, Richard NE, Modell JG. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. *Biological Psychiatry* 57(7): 793-801, 2005.
35. Knyshevski I, Connor DF, Harrison RJ, Ricci LA, Melloni, Jr. RH: Persistent activation of select forebrain regions in aggressive, adolescent cocaine-treated hamsters. *Behavioural Brain Research* 159 (2): 277-286, 2005.
36. Barkley RA, Murphy KR, O'Connell T, Connor DF: Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder. *Journal of Safety Research* 36: 121-131, 2005.
37. Jackson D, Burns R, Trksak G, Simeone B, DeLeon KR, Connor DF, Harrison RJ, Melloni, Jr., RH: Anterior hypothalamic vasopressin modulates the aggression-stimulating effects of adolescent cocaine exposure in Syrian hamsters. *Neuroscience* 133: 635-646, 2005.
38. Connor DF, McLaughlin TJ: A naturalistic study of medication reduction in a residential treatment setting. *Journal of Child and Adolescent Psychopharmacology* 15(2): 302-310, 2005.
39. **Bambauer KZ, Connor DF: Characteristics of aggressive behavior in psychiatrically referred children. *CNS Spectrums* 10(9): 709-718, 2005.

40. Connor, DF, Spencer TJ: Short-term cardiovascular effects of mixed amphetamine salts extended release in children and adolescents with oppositional defiant disorder. *CNS Spectrums* 10(10) (Suppl 15): 31-38, 2005.
41. Barkley RA, Murphy KR, O'Connell T, Anderson D, Connor DF: Effects of two doses of alcohol on simulator driving performance in adults with attention deficit hyperactivity disorder. *Neuropsychology* 20(1): 77-87, 2006.
42. Rappaport N, Frazier JA, Connor D, Mattison R: From Zero to a Hundred in a Split Second: Understanding Aggression in an Eight-Year-Old Child. *Harvard Review of Psychiatry* 14:165-176, 2006.
43. Connor, DF, Carlson G, Chang K, Daniolos P, Ferziger R, Findling R, Hutchinson J, Malone R, Halperin J, Plattner B, Post R, Reynolds D, Rogers K, Saxena K, Steiner H: Juvenile maladaptive aggression: a review of prevention, treatment, service configuration, and a proposed research agenda. *Journal of Clinical Psychiatry* 67(5): 808-820, 2006.
44. Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R. The safety and efficacy of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attention deficit/hyperactivity disorder in school age children and adolescents: A 4-week, multicenter, randomized, double-blind parallel-group, placebo-controlled, forced-dose-escalation study. *Clinical Therapeutics* 28:402-418, 2006.
45. Connor DF, McLaughlin TJ: Aggression and diagnosis in psychiatrically referred children. *Child Psychiatry and Human Development* 37:1-14, 2006.
46. Connor DF, McLaughlin TJ, Jeffers-Terry M, O'Brien WH, Stille CJ, Young LM, Antonelli RC. Targeted child psychiatric services: A new model of pediatric primary clinician-child psychiatry collaborative care. *Clinical Pediatrics* 45: 423-434, 2006.
47. Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS: Pharmacotherapy of aggression in children and adolescents: Efficacy and effect size. *Journal of the Canadian Academy of Child & Adolescent Psychiatry* 15(1): 27-39, 2006.
48. Doerfler LA, Connor DF, Volungis AM, Toscano PF: Panic disorder in clinically referred children and adolescents. *Child Psychiatry and Human Development* 38: 57-71, 2007.
49. Ricci LA, Connor DF, Morrison R, Melloni, Jr., RH: Risperidone exerts potent anti-aggressive effects in a developmentally immature animal model of escalated aggression. *Biological Psychiatry* 62: 218-225, 2007.
50. Connor DF, Doerfler LA, Ford JD, Albert DB: Conduct disorder subtype and comorbidity. *Annals of Clinical Psychiatry* 19(3): 161-168, 2007.
51. Kaminer Y, Connor DF, Curry JF: Comorbid adolescent substance use and major depressive disorders: A review. *Psychiatry* 4(12):32-41, 2007.
52. Doerfler LA, Toscano PF, Jr., Connor DF: Separation anxiety and panic disorder in clinically referred youth. *Journal of Anxiety Disorders* 22:602-611, 2008.
53. Connor DF, McLaughlin TJ, Jeffers-Terry M: A randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. *Journal of Child & Adolescent Psychopharmacology* 18(2):140-156, 2008.

54. Connor DF, Doerfler LA: ADHD with comorbid ODD/CD: Discrete or non-distinct disruptive behavior disorders? *Journal of Attention Disorders* 12(2): 126-134, 2008.
55. Schwartz JJ, Connor DF, Morrison R, Ricci LA, Melloni, Jr., R: Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression. *Physiology & Behavior* 95:176-181, 2008.
56. Charlot L, Deutsch CK, Albert A, Hunt A, Connor DF, McIlvane, Jr. WJ: Mood and anxiety symptoms in psychiatric inpatients with autism spectrum disorder and depression. *Journal of Mental Health Research in Intellectual Disabilities* 1(4): 238-253, 2008
57. Kaminer Y, Connor DF, Curry JF: Treatment of comorbid adolescent cannabis use and major depressive disorder. *Psychiatry* 5(9): 34-39, 2008.
58. Doerfler LA, Toscano PF, Jr., Connor DF. Sex and aggression: The relationship between gender and abuse experience in youngsters referred to residential treatment. *Journal of Child and Family Studies* 18(1): 112-122, 2009.
59. Connor DF, Doerfler LA: Attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder or conduct disorder. *Current Attention Disorder Reports* 1(1): 5-11, 2009.
60. Ford JD, Connor DF: ADHD and posttraumatic stress disorder. *Current Attention Disorder Reports* 1(2): 60-66, 2009.
61. Findling RL, Connor DF, Wigal T: A linguistic analysis of in-office dialogue among psychiatrists, parents, and child and adolescent patients with ADHD. *Journal of Attention Disorders* 13(1):78-86, 2009.
62. Ford JD, Connor DF, Hawke J. Complex trauma among psychiatrically impaired children. *Journal of Clinical Psychiatry* 70(8):1155-1163, 2009.
63. **Ford JD, Fraleigh LA, Connor DF: Child abuse and aggression among seriously emotionally disturbed children. *Journal of Clinical Child & Adolescent Psychology* 39(1): 25-34. 2010.
64. Kaminer Y, Goldberg P, Connor DF: Psychotropic medications and substances of abuse: Interactions in youth. *Substance Abuse* 31: 53-57, 2010.
65. Ford JD, Elhai JD, Connor DF, Frueh CB: Poly-victimization and risk of posttraumatic, depressive, and substance use disorders and involvement in delinquency in a national sample of adolescents. *Journal of Adolescent Health* (In Press).

OTHER PUBLICATIONS

1. Connor, DF: Current Status of Clonidine in ADHD. *The ADHD Report* 2: 5-6, 1994
2. Swanson, JM, Flockhart, D, Udrea, D, Cantwell, D, Connor, D, Williams, L (Letter to the Editor): Clonidine in the Treatment of ADHD: Questions About Safety and Efficacy. *Journal of Child and Adolescent Psychopharmacology* 5: 301-304, 1996

3. Connor, DF (Invited Book Review): Pediatric Psychopharmacology: I. MA Riddle (Ed). Journal of the American Academy of Child and Adolescent Psychiatry 35: 548-549, 1996
4. Connor, DF, Harrison, RJ, Melloni, Jr., RH: Aggression and Psychopharmacology in Clinically Referred Children and Adolescents. The ADHD Report 4: 3-7, 1996
5. Connor, DF, Steingard, RJ: A Clinical Approach to the Pharmacotherapy of Aggression in Children and Adolescents. In: CF Ferris, T Grisso (Eds), Understanding Aggressive Behavior in Children, New York, New York Academy of Sciences Press, 1996, pp 290-307
6. Connor, DF (Letter to the Editor): Stimulants and Neuroleptic Withdrawal Dyskinesia. Journal of the American Academy of Child and Adolescent Psychiatry 37:247-248, 1998
7. Connor DF, Harrison RJ, Melloni Jr. RH: Biogenic Amines and the Psychopharmacology of Aggression. Expert Opinion on Therapeutic Patents 8:349-359, 1998
8. Connor DF, Posever TA, Haynes K: Novel Antipsychotics in Child and Adolescent Psychiatry. NEECAP Bulletin, September, 1997 - June, 1998
9. Connor DF, Swanson JM: Clonidine and Guanfacine in the Treatment of Children with ADHD and Associated Conditions: A Mini-Review. Child and Adolescent Psychopharmacology News 4:1-8, 1999
10. Wilens TE, Spencer TJ, Swanson JM, Connor DF, Cantwell D (Debate Forum): Combining Methylphenidate and Clonidine. Journal of the American Academy of Child and Adolescent Psychiatry 38:614-622, 1999
11. Barkley RA, (Connor DF, one of 90 authors). Consensus statement on ADHD. European Child & Adolescent Psychiatry, 11(2): 96-98, 2002
12. Connor DF (Commentary): Review: once a day Concerta methylphenidate was equivalent to 3 times daily methylphenidate in children with ADHD. Evidence-Based Mental Health 5: 20, 2002
13. Connor DF (Commentary): Review: short acting methylphenidate has short-term efficacy in children and adolescents with attention deficit disorder. Evidence Based Mental Health 5: 50, 2002
14. Connor DF: Aggression and antisocial behavior in youth. The Brown University Child and Adolescent Behavior Letter 9 (18): 1-4, 2002
15. Connor DF, Doerfler LA, Volungis, AM, Steingard RJ, Melloni, Jr., RH: Aggressive behavior in abused children. New York Academy of Sciences 1008, 79-90, 2003.
16. Connor DF. Paroxetine and the FDA (Letter to the Editor). Journal of the American Academy of Child and Adolescent Psychiatry 43(2), 127, 2004.
17. Steingard R, Connor, DF: The neurobiology of attention. Health in Action 2(4), 5, 2004.
18. Abikoff H, Connor D, Pliszka S, Boeliner F, Lopez F, Mays D, Read S, Palmer S, Tulloch S: Distinguishing treatment effects of oppositional defiant disorder from ADHD. Current ADHD Insights 3(5), 21-22, 2004.
19. Findling RL, Connor DF, McCracken JT, Wigal S: Pharmacologic treatment of childhood attention-deficit/hyperactivity disorder: Current options and new developments. CNS News Special Report, February, 2006.

20. Connor DF: Psychiatric Commentary: Risk-benefit considerations in ADHD pharmacotherapy. First Report, University of Cincinnati College of Medicine and Princeton Media Associates, October 20, 2006.
21. Connor DF: Pharmacological Treatment of ODD Symptoms in ADHD Children: A Brief Review. *The ADHD Report* 15 (1), 1-6, Guilford Press, 2007.
22. Connor DF: Clinical Trials Report (Guanfacine extended release in children and adolescents with ADHD). *Current Attention Disorders Reports* 1(1): 1-2, 2009.
23. Fraleigh LA, Hendratta VD, Ford JD, Connor DF (letter): Prazosin for the treatment of posttraumatic stress disorder-related nightmares in an adolescent male. *Journal of Child & Adolescent Psychopharmacology* 19(4): 475-476, 2009.

BOOK CHAPTERS

1. DuPaul, GJ, Barkley, RA, Connor, DF: Stimulant Medication. In: RA Barkley (Ed), *Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment*, revised edition, New York, Guilford Publications, pp. 510-551, 1998
2. Connor, DF: Other Medications in the Treatment of Child and Adolescent Attention-Deficit Hyperactivity Disorder. In: RA Barkley, (Ed), *Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment*, revised edition, New York, Guilford Publications, pp. 564-581, 1998
3. Barkley, RA, DuPaul, GJ, Connor, DF: Stimulants. In: JS Werry, MG Aman (Eds), *Practitioners Guide to Psychoactive Drugs for Children and Adolescents*, 2nd ed., New York, Plenum Publishing Co., pp. 213-247, 1999
4. Regino R, Baren M, Connor D, Swanson J. Patterns of use of clonidine alone and in combination with methylphenidate. In: LL Greenhill, BB Osman (Eds.), *Ritalin: Theory and Practice*, 2nd ed., New York: Mary Ann Liebert, pp. 381-384, 1999
5. Barkley RA, DuPaul GJ, Connor DF: The Stimulants. In: Barkley RA, *Taking Charge of ADHD* (revised edition). New York: Guilford, 2000
6. Steingard RJ, Connor DF, Au T: Approaches to psychopharmacology. In: Bauman ML & Kemper TL (Eds.), *The Neurobiology of Autism*, Second Edition. Baltimore: The Johns Hopkins University Press, pp. 79-102, 2005.
7. Connor DF: Psychostimulants in ADHD: Theoretical and practical issues for the community practitioner. In: Gozal, D & Molfese DL (Eds.), *Attention Deficit Hyperactivity Disorder: From Genes to Patients*. Totowa, NJ: Humana Press, pp. 485-527, 2005.
8. Connor DF. Stimulants in attention deficit/hyperactivity disorder. In: Barkley, RA (Ed.), *Attention-Deficit Hyperactivity Disorder*, Third Edition. New York: Guilford Press, 608-647, 2006.
9. Connor DF. Other medications for attention deficit/hyperactivity disorder. In: Barkley, RA (Ed.), *Attention-Deficit Hyperactivity Disorder*, Third Edition. New York: Guilford Press, pp. 658-677, 2006.
10. Connor DF: Aggression. In: Reyes G, Elhai J, Ford J (Eds.). *Encyclopedia of Psychological Trauma*. Hoboken, NJ: John Wiley & Sons, pp. 19-20, 2008.

11. Connor, D., & Fraleigh, L. Pharmacotherapy (child). In G. Reyes, J. D. Elhai, & J. D. Ford (Eds.), *Encyclopedia of Psychological Trauma*. Hoboken New Jersey: John Wiley & Sons, pp. 471-474, 2008.
12. Connor DF. Family factors in etiology and family-based intervention. In Schneider BH, Alles-Jardel M, Normand S, Provost, M, & Tarabulsky G (Editors), *Violence and Aggressive Behaviors By Children and Adolescents (French)*. Presses de l'Universitaire du Quebec, 2009, pp. 107-133.
13. Connor DF: Disruptive Behavior Disorders. In: Sadock BJ, Sadock, VA, Ruiz P (Eds.). *Kaplan & Sadock's Comprehensive Textbook of Psychiatry*, ninth edition. Philadelphia: Lippincott Williams & Wilkins, 2009, pp. 3580-3596.
14. Connor DF: ECT, Deep Brain Stimulation, and TMS. In: Dulcan M (Ed.). *American Psychiatric Association Textbook of Child & Adolescent Psychiatry*, third edition. Washington DC: American Psychiatric Association Press, pp. 795-804, 2009.
15. Connor, D., & Fraleigh, L. Antisocial behavior. In I. Weiner, & E. Craighead (Eds.), *Corsini's Encyclopedia of Psychology*, fourth edition. Hoboken, NJ: John Wiley & Sons, pp. 126-129, 2010.
16. Doerfler LA, Toscano PF, Connor DF: Panic Disorder. In: Levesque RJR (Editor). *Encyclopedia of Adolescence*. New York, NY: Springer, 2010. (In Press).

ABSTRACTS AND POSTER PRESENTATIONS:

1. Cantwell, DP, Swanson, JM, Connor, DF: Side Effects of Clonidine in the Treatment of Children with ADHD: Cases from Nonfatal Medwatch Reports. 7th International Society for Research in Child and Adolescent Psychopathology. Santa Monica, CA. 1996
2. Melloni, Jr., RH, Harrison, RJ, Connor, DF, Ferris, CF: Adolescent Anabolic Steroids, Vasopressin, and Aggression in Golden Hamsters. *Journal of Neuroscience Abstracts* 22(3), p. 2068, 1996
3. Harrison, RJ, Connor, DF, Melloni, Jr., RH: Neuroleptics, Neuromodulation, and Aggression. Second Annual International Colloquium on Aggression, Mental Illness, and Psychiatric Intervention, Philippe Pinel Institute Research Center, Montreal (Quebec), 1996
4. Melloni, Jr., RH, Connor, DF, Harrison, RJ: Preclinical Models of Adolescent Anabolic Steroid Abuse and Aggression. Second Annual International Colloquium on Aggression, Mental Illness, and Psychiatric Intervention, Philippe Pinel Institute Research Center, Montreal (Quebec), 1996
5. Connor, DF: Child and Adolescent Aggression and Comorbidity. Scientific Proceedings of the 43rd Annual Meeting of Child and Adolescent Psychiatry, Philadelphia, Pennsylvania, 1996
6. Melloni, Jr., RH, Connor, DF, Nash, K, Harrison, RJ: Chronic Anabolic Steroid Exposure During Adolescence Stimulates Vasopressin-Dependent Aggression in Hamsters. *Journal of Neuroscience Abstracts* 23 (2), p. 1870, 1997

7. Harrison RJ, Connor DF, Melloni Jr. RH: Chronic Cocaine Exposure During Adolescence Elevates Offensive Aggression in Adult Golden Hamsters. Society for Neuroscience Press Book, 1998
8. Melloni Jr. RH, Connor DF, Harrison RJ: Chronic Anabolic Steroid Exposure During Adolescence Stimulates Vasopressin-Dependent Aggression in Hamsters. Society for Neuroscience Press Book, 1998
9. Harrison, RJ, Connor, DF, Nowak, C, Melloni, Jr., RH: Chronic Cocaine Treatment Alters Offensive Aggression in Golden Hamsters. Journal of Neuroscience Abstracts 23(2), p. 1094, 1997
10. Harrison, RH, Connor, DF, Alexander, M.J., Melloni, R.H., Jr. Adolescent cocaine and flank marking in female hamsters. Journal of Neuroscience Abstracts, p. 1001, 2000
11. Connor, DF, Cunningham, JA, Anderson, JJ, Steingard, RJ, Melloni, RH, Jr. Proactive and reactive aggression in referred children and adolescents. International Society for Research on Aggression, 15th Meeting, Montreal (Quebec), 2002
12. Cunningham, JA, Connor, DF, Melloni, RH, Jr. Unique correlates of expressed and perceived hostility in a population of psychiatrically referred youth. International Society for Research on Aggression, 15th Meeting, Montreal (Quebec), 2002
13. Melloni, Jr., RH, Connor, DF, Grimes, JM, Karper, P, Ricci, LA. Repeated adolescent cocaine exposure activates primary aggression areas in hamster brain. Annual Society for Neuroscience Meeting, Orlando, Florida, November, 2002
14. Connor, DF, Doerfler, LA, Volungis, AM, Melloni, Jr., RH. Child abuse, conflict, and aggression. New York Academy of Sciences Conference on The Roots of Mental Illness in Children, Rockefeller University, New York, NY, March, 2003
15. Connor DF, Hudziak JJ, Wilens TE, Haight BR, Horrigan JP, Hampton KD, Richard NE, Modell JG. A controlled trial of extended-release bupropion in adult ADHD. 44th Annual NIMH New Clinical Drug Evaluation Unit (NCDEU) Meeting, Phoenix, AZ, June 2, 2004.
16. Abikoff HB, Connor DF, Spencer T, Pliszka SR, Boellner SW, Lopez FA, Sea DA, Mays DA, Read SC, Tulloch SJ. Distinguishing treatment effects of oppositional defiant disorder from attention deficit/hyperactivity disorder. 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC, October 22, 2004.
17. Connor DF. Cardiovascular safety of mixed amphetamine salts extended release in children and adolescents with oppositional defiant disorder. 52nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Toronto, Canada, 2005.
18. Ricci LA, Connor DF, Morrison R, Melloni, Jr. RH. Risperidone and the behavioral pharmacology of escalated aggression. Society for Neuroscience, Washington, DC, November 2005.
19. Doerfler LA, Toscano PF, Volungis AM, Connor DF. Panic disorder in clinically referred children and adolescents. Association for Behavioral and Cognitive Therapies, 39th Annual Convention, Washington, DC, November 17-20, 2005.

20. Connor DF. Cardiovascular safety of mixed amphetamine salts XR in the treatment of patients with ODD. U.S. Psychiatric and Mental Health Congress, Las Vegas, Nevada, November 2005.
21. Connor DF, Antonelli RC, McLaughlin TJ. Targeted Child Psychiatric Services: A new collaborative model of pediatric-child psychiatry care. Pediatric Academic Societies' Annual Meeting, San Francisco, CA, April 29-May 2, 2006.
22. Connor DF, McLaughlin TJ, Jeffers-Terry, M. A Randomized, Controlled, Pilot Study of Quetiapine in the Treatment of Adolescent Conduct Disorder. American Psychiatric Association Annual Meeting, Toronto, Canada, May 20-May 25, 2006.
23. Toscano PF, Doerfler, LA, Connor DF, Fight-or-Flight: Relationship of Anxiety, Oppositionality, and Aggression in a Clinical Population of Youth. Association for Behavioral and Cognitive Therapies 40th Annual Convention, Chicago, IL, November 16-19, 2006.
24. Doerfler LA, Toscano PF, Connor DF, Separation Anxiety Hypothesis and Panic Disorder in Youngsters. Association for Behavioral and Cognitive Therapies 40th Annual Convention, Chicago, IL, November 16-19, 2006.
25. Schwartz, J.J., Ricci, L.A., Connor, D.F., Morrison, R., Melloni, R.H., Jr (2006) Risperidone prevents the phenotypic expression of adolescent cocaine-induced offensive aggression in the syrian hamster: a developmental and neuropharmacological analysis. *Journal of Neuroscience Abstracts*. 32, #198.1.
26. Findling RL, Connor DF, Wigal T, Eagan C, Nelson M (2007). A sociolinguistic analysis of in-office dialogue about ADHD and psychiatric comorbidities among psychiatrists, child and adolescent patients and their parents. 20th annual U.S Psychiatry & Mental Health Congress, October 11-14, 2007; Orlando, Florida.
27. Doerfler LA, Toscano PF, Connor DF (2007). Gender differences in youngsters in residential treatment. Association for Behavioral and Cognitive Therapies 41st Annual Convention, Philadelphia, PA, November 15-18, 2007.
28. Rashid A, Hashmi SM, Hawke JM, Pearson GS, Connor DF (2008). A pilot study of aggression subtype in seriously emotionally disturbed adolescent girls. Presented at the American Academy of Child & Adolescent Psychiatry, 55th Annual Meeting, Chicago, IL, October 28–November 2. Also presented at the European Society for Child and Adolescent Psychiatry International Conference, Budapest, Hungary, August 22-29, 2009.
29. Doerfler LA, Connor DF (2008). Differentiating childhood bipolar disorder and ADHD. Association for Behavioral and Cognitive Therapies, 42nd Annual Meeting, Orlando, FL, November 13-16.
30. Sallee FR, Spencer TJ, Connor DF, Lopez FA, Lyne A, Tremblay G (2009). Effects of guanfacine extended release on secondary measures in children with attention-deficit/hyperactivity disorder and oppositional symptoms. Society of Biological Psychiatry, 64th Annual Meeting, Vancouver, Canada, May 14-16.
31. Connor DF, et al. (2009). Effects of guanfacine extended release on secondary measures in children with attention-deficit/hyperactivity disorder and oppositional symptoms. American Psychiatric Association, 162nd Annual Meeting, San Francisco, CA, May 16-21.

32. Charlot L, Deutsch CK, Albert A, Hunt A, Connor DF, Mcilvane WJ (2009). Mood and anxiety symptoms in psychiatric inpatients with autism spectrum disorder and depression. Gatlinburg Conference on Research & Theory in Intellectual & Developmental Disabilities, 42nd Annual Conference, New Orleans, Louisiana, March 18-20.
33. Fanton J, Waslick B, Harvey E, Connor D, Recoulle A, Martin B, Olney E (2009). Effectiveness of an extended release stimulant in treating preschool children with ADHD. New Clinical Drug Evaluation Unit (NCDEU), Annual Meeting Hollywood Florida, 6/29-7/3.
34. Doerfler LA, Toscano PF, Connor DF. Complex dysregulation and the CBCL in clinically referred youngsters: A new phenotype? Association for Behavioral and Cognitive Therapies, 43rd Annual Meeting, New York, November 19-22, 2009.
35. Doerfler LA, Doring EM, Toscano PF, Connor DF. Developmental origins of reactive and proactive aggression in two clinical samples. Association for Behavioral and Cognitive Therapies, 43rd Annual Meeting, New York, November 19-22, 2009.
36. Hawke JM, Ford JD, Connor DF (2009). Clinically significant differences among juveniles with externalizing disorders. American Society of Criminology, Philadelphia, PA, November 4-7.
37. Lopez FA, Kollins SH, Spencer TJ, Findling RL, Sallee FR, Connor DF, Lyne A, Tremblay G (2009). Effects of guanfacine extended release in children aged 6 to 12 years with oppositional symptoms and a diagnosis of Attention-Deficit Hyperactivity Disorder. American Professional Society for ADHD and Related Disorders (APSARD), Philadelphia, PA, November 13, 2009. Also presented: AACAP Honolulu Hawaii, October 2009.
38. Shepski JC, Lopez FA, Connor DF, Spencer TJ, Sallee FR, Lyne A, Tremblay G. (2009). Effects of guanfacine extended release on disruptive behavior, parental stress, and global improvement in children with Attention Deficit/Hyperactivity Disorder and oppositional symptoms. Society for Developmental and Behavioral Pediatrics (SDBP), Portland, OR, October 5, 2009.

FEDERAL GRANT ACTIVITY

1. Barkley, RA: Principal Investigator: Driving skills in ADHD Teenagers, NIH 5 RO1HD28171
 - a. Connor, DF: Co-Investigator: 15% support 7/2003 – 12/2004
2. McIlvane, W: Principal Investigator: Depression in Children with Mental Retardation, NIH 1 RO1HD042807
 - a. Connor, DF: Co-Investigator: 10% support 9/2006 – 9/2008

GRANTS AND CONTRACTS:

1. 1994: Connor, D. F., (Principal Investigator): Ritalin and/or Clonidine for Aggressive Children with ADHD. Small Grants Program Award, University of Massachusetts Medical School. Direct costs only: \$10,000

2. 1995: Barkley, R.A. & Connor, D.F. (Co-Principal Investigators): Response of ADHD Adolescents to Adderall and Methylphenidate. Richwood Pharmaceuticals: Direct and Indirect costs: \$33,536.
3. 1996: Connor, D.F. (Principal Investigator) & Barkley, R.A. (Co-Investigator): A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Four Oral Doses of 1555U88 in the treatment of Attention Deficit/Hyperactivity Disorder in Adults. Glaxo Wellcome: Direct and Indirect costs: \$50,000.
4. 1997-98: Connor, D.F. (Principal Investigator): HFBE atomoxetine. Eli Lilly and Company: Direct and Indirect Costs: \$105,120
5. 1997-99: Connor, D.F. (Principal Investigator): HFBF atomoxetine. Eli Lilly and Company: Direct and Indirect Costs: \$40,816
6. 1998-99: Connor, D.F. (Principal Investigator): HFBK atomoxetine. Eli Lilly and Company: Direct and Indirect Costs: \$48,941
7. 1999-2000: Connor, D.F. (Principal Investigator): LYAI atomoxetine. Eli Lilly and Company: Direct and Indirect Costs: \$6,393
8. 1999: Connor, D.F. (Principal Investigator) and Ozbayrak, R.K. (Co-Investigator): SLI381.301 Adderall XR. Shire Laboratories: Direct and Indirect Costs: \$73,195
9. 1999-2000: Ozbayrak, R.K. (Principal Investigator) and Connor, D.F. (Co-Investigator): SLI381.302 Adderall XR. Shire Laboratories: Direct and Indirect Costs: \$60,200
10. 2000: Ozbayrak, R.K. (Principal Investigator) and Connor, D.F. (Co-Investigator): SLI381.302 Adderall XR Extension Study, Shire Laboratories: Direct and Indirect Costs: \$31,000
11. 2001: Connor, D.F. (Principal Investigator) & Ozbayrak, R.K. (Co-Investigator): Modafinil. Cephalon, Inc.: Direct and Indirect Costs: \$89,595
12. 2001: Connor, D.F. (Principal Investigator): Unrestricted educational grant in support of the University of Massachusetts/Memorial Health Care monthly pediatric neuropsychiatry case conference. McNeil Pharmaceuticals: \$6000
13. 2001-02: Connor, D.F. (Principal Investigator): The Devereux Early Developmental Stress and Aggression Project: Devereux Institute for Clinical Training and Research, Villanova, PA. Direct Costs: \$20,000
14. 2002: Connor, D.F. (Principal Investigator): Unrestricted educational grant in support of the University of Massachusetts/Memorial Health Care monthly pediatric neuropsychiatry case conference. Shire Pharmaceuticals, Inc: \$5040
15. 2003: Connor, D.F. (Principal Investigator): A 4-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Provigil (Modafinil) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder, Followed by an 8-Week Open-Label Extension. Cephalon, Inc. Direct and Indirect Costs: \$10,645.
16. 2003: Connor, D.F. (Principal Investigator): A 5-week, multicenter, double-blind, fixed-dose study of the efficacy and safety of Focalin™ LA (dexamethylphenidate hydrochloride extended-release capsules) administered once daily in adults with Attention-Deficit/Hyperactivity Disorder. Novartis Pharmaceuticals Corporation, Direct and Indirect Costs: \$65,000.

17. 2003: Connor, D.F. (Principal Investigator): An 8-week, multicenter, randomized, double-blind, placebo-controlled, flexible dose comparison of extended-release bupropion hydrochloride 300-450 mg/day to assess the efficacy, safety, and effects on health outcomes in the treatment of adults with Attention-Deficit/Hyperactivity Disorder. GlaxoSmithKline, Direct and Indirect Costs: \$50,000.
18. 2002-05: Investigator Initiated Grant: Connor, DF (Principal Investigator): Quetiapine (Seroquel®) for aggression, oppositional-defiant behavior, and conduct problems in children and adolescents with conduct disorder. AstraZeneca, Direct and Indirect Costs: \$295,000.
19. 2003: Restricted Educational Grant: Connor, DF: Purchase of pediatric psychopharmacology textbooks (40) for pediatric residents and child and adolescent psychiatry fellows at the University of Massachusetts Medical School. Janssen Pharmaceuticals, Direct Cost: \$2000.
20. 2004: Restricted Educational Grant: Connor, DF: Purchase of pediatric psychopharmacology textbooks (24) for pediatric residents and child and adolescent psychiatry fellows at the University of Massachusetts Medical School. Shire Pharmaceuticals, Direct Cost: \$3120.
21. 2004: Connor, D.F. (Principal Investigator): Unrestricted educational grant in support of the University of Massachusetts/Memorial Health Care monthly pediatric neuropsychiatry case conference. AstraZeneca Pharmaceuticals, Direct Cost: \$4000.
22. 2004: Connor, DF (Principal Investigator): Internal Department of Psychiatry Award: Targeted Child Psychiatric Services Evaluation Grant. Direct Costs only: \$16,000.
23. 2005: Connor, D.F. (Principal Investigator): A phase III, randomized, double-blind, multi-center, placebo-controlled, parallel-group, safety and efficacy study of SPD 465-301 in adults with attention-deficit hyperactivity disorder (ADHD). SPD465-301. Shire Pharmaceuticals, U.S., direct and indirect costs \$105,000.
24. 2005: Connor, D.F. (Principal Investigator): A phase III, multi-center, 12-month, open-label safety study of SPD465-304 in adults with attention deficit/hyperactivity disorder. SPD465-304. Shire Pharmaceuticals, U.S.
25. 2005: Connor, D.F. (Principal Investigator): Outcomes assessment of a new model of primary clinical/child psychiatry collaborative care. The Meyers Primary Care Institute of the University of Massachusetts Medical School, the Fallon Foundation, and the Fallon Community Health Plan, Worcester, MA. Direct Costs \$15,000.
26. 2006: Connor, D.F. (P.I.): Unrestricted educational grant. Shire Pharmaceuticals, U.S. \$3000.
27. 2005-2007: Investigator Initiated Grant. Melloni, Jr., R.H. and Connor, D.F. (Co-Principal Investigators): Risperidone and the behavioral pharmacology of escalated aggression. Janssen Pharmaceuticals, UCHC Direct and Indirect Costs: \$33,000.
28. 2007-2009: Connor DF (P.I.); unrestricted educational grant. University of Connecticut Health Center Monthly Collaborative ADHD Case Conference Series

- with the University of Connecticut Department of Pediatrics at CCMC. Shire Pharmaceuticals, Direct Costs only: \$28, 893.
29. 2007-2008: Connor DF; Abbott Study M06-888 A Randomized, double-blind, placebo-controlled, parallel-group, Phase 2 dose-ranging study of the safety and efficacy of ABT-089 in children with Attention Deficit-Hyperactivity Disorder (ADHD). Data Safety Monitoring Committee. \$17,000.
 30. 2008-2009: Connor DF; Abbott Study M10-178 The long-term safety and tolerability of ABT-089 in children with Attention Deficit-Hyperactivity Disorder (ADHD). Data Safety Monitoring Committee. \$17,000.
 31. 2008-2009: Connor DF; Abbott Study M10-345 A Randomized, double-blind, placebo-controlled, parallel-group, phase 2 dose-ranging study of the safety and efficacy of ABT-089 in children with Attention Deficit-Hyperactivity Disorder (ADHD). Data Safety Monitoring Committee. \$17,000.
 32. 2009-2010: Connor DF; Educational Grant: Videotape Educational Tools to Enhance Medical Student Education in Child & Adolescent Psychiatry. Kaiser Permanente Endowment: \$2160.

AWARDS

1. The Annapolis Coalition on the Behavioral Health Workforce (SAMSA): Selection of Targeted Child Psychiatric Services for inclusion in the national Registry of Innovative Practices in Workforce Development.
2. Award of Tenure; University of Connecticut SOM; Department of Psychiatry: 9/1/2008.

EDITORIAL BOARD

1. The ADHD Report: Editor: Russell A. Barkley, PhD. New York, NY: Guilford Press. (2006 to present)
2. The Journal of Attention Disorders: Editor: Sam Goldstein, PhD. Thousand Oaks, CA: Sage Publications. (May 2007 to present)
3. Current Attention Disorder Reports: Editor: Anthony L. Rostain, M.D. Current Medicine Group, LLC, Philadelphia, PA. (February 2008 to present)
 - a. Section Editor: ADHD and Comorbidity

JOURNAL MANUSCRIPT REVIEWER

1. Expert Opinion on Neurotherapeutics
2. CNS Spectrums
3. Journal of the American Academy of Child and Adolescent Psychiatry
4. American Journal of Psychiatry
5. Commentator for Journal of Evidenced-Based Mental Health
6. Journal of Child and Adolescent Psychopharmacology
7. Pediatrics
8. Expert Review of Neurotherapeutics
9. Hormones and Behavior

10. Pediatric Drugs
11. Acta Psychiatrica Scandinavica
12. Biological Psychiatry
13. Personality and Individual Differences
14. Journal of Child Psychology and Psychiatry
15. Journal of Clinical Child and Adolescent Psychology
16. Child Psychiatry & Human Development
17. Journal of Adolescence
18. Journal of Attention Disorders
19. Current Psychiatry
20. Annals of Clinical Psychiatry
21. Journal of Clinical Psychiatry
22. Child and Adolescent Mental Health
23. Learning and Individual Differences

AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY: EXAMINER

1. Examiner: Psychiatry Part II Oral Boards: The American Board of Psychiatry and Neurology. Boston, MA, 5/10/04 – 5/11/04.
2. Examiner: Child & Adolescent Examinations: The American Board of Psychiatry and Neurology, Atlanta, Georgia, 11/11/05 – 11/13/05.

CONSULTANT

1. Massachusetts Executive Office of Health & Human Services, Office of Clinical Affairs 1/1/02 –9/30/05.
2. Consultant to North East Massachusetts Law Enforcement Council, School Threat Assessment Response System (NEMLEC STARS) 7/2001-6/2003.
3. The Oak Group: Consultant on developing psychiatric standards of care for the health insurance industry 9/1999 – present.

SERVICE ACTIVITIES

1. Ad Hoc Reviewer: National Institutes of Mental Health Trauma and Violence Subsection Grants, 2000
2. New England Council of Child and Adolescent Psychiatry: Board Member 1998-2000
3. Devereux National Medical Advisory Board 1996-2002
4. Massachusetts Behavioral Health Partnership Clinical Advisory Board: 2000-2001
5. New England Partnership for Appropriate Psychoactive Medication Prescribing: 2002-2005
6. Stanford-Howard Medical School Work Group on Juvenile Impulsive Aggression (Sponsored by Ortho McNeil Pharmaceuticals), 2002 to present.
7. Massachusetts Child Psychiatry Access Project (MCPAP) Advisory Committee 1/02 – 9/05.

8. Annie E. Casey Foundation, Baltimore, MD: Juvenile Impulsive Aggression Conference, 11/4/04-11/5/04-Invited Participant
9. Psychiatric Medication Advisory Committee (PMAC), Department of Children and Families, Riverview Hospital for Children and Youth, Middletown, CT, 10/7/05-present.
10. The Annapolis Coalition on Manpower Issues in Mental Health. SAMSA, Washington, DC, 11/7/05-11/8/05-Invited Participant
11. The Connecticut Center for Effective Practice. Board Member, Farmington, CT, 2/2006 to present
12. Consensus Meeting on Outpatient Management of Aggression in Youth: Treatment Recommendations, Appropriate and Inappropriate Medication Uses, Alternative Interventions, and Research Priorities. NIH. Dallas, TX, 2/12-2/13/07-Invited Participant.
13. Connecticut Nurturing Families Network Advisory Board 1/2008 to present.

PHARMACEUTICAL INDUSTRY ADVISORY BOARD

1. Shire Richwood Pharmaceuticals ADHD Expert Advisory Board, 1995 to present.
2. Johnson-McNeil Pharmaceuticals ADHD Expert Advisory Board, 1998-2000.
3. Eli-Lilly Pharmaceuticals ADHD Expert Advisory Board, 1997–2002.
4. AstraZeneca Pharmaceuticals Seroquel Investigator Initiated Trials Consultant, 2001 – 2005.
5. Bolt International Healthcare & Pharmaceutical Research ADHD Thought-Leader Panel, 7/2000 to 7/2002.
6. Harris Interactive ADHD Expert Panel, 7/1999 to 7/2001.
7. Cephalon, Inc. ADHD Expert Advisory Board, 1/2006 to 1/2007.

PHARMACEUTICAL INDUSTRY SPEAKER'S BUREAU

1. Shire Richwood Pharmaceuticals ADHD Speaker's Bureau, 1997 – present.
2. Johnson-McNeil Pharmaceuticals ADHD Speaker's Bureau, 1998.
3. Eli-Lilly Pharmaceuticals ADHD Speaker's Bureau, 1996 – 2002.

LICENSURE AND CERTIFICATION:

- 1983 Commonwealth of Massachusetts Medical License
- 1983 Diplomate National Board of Medical Examiners
- 1987 American Board of Psychiatry and Neurology – Adult Psychiatry
- 1989 American Board of Psychiatry and Neurology – Child and Adolescent Psychiatry
- 2005 State of Connecticut Medical License

PROFESSIONAL MEMBERSHIPS

- American Academy of Child and Adolescent Psychiatry, 1987 to present.
- New England Council for Child and Adolescent Psychiatry, 1995 to 2005.

- International Society for Research on Aggression (ISRA), 2002 to present.
- International Society for Research in Child & Adolescent Psychopathology (ISRCAP), 2003 to present.
- American Psychiatry Association, 1983 to 2003.
- Society of Professors of Child and Adolescent Psychiatry, 1/2007 to present.

PROFESSIONAL INTERESTS

- General Child and Adolescent Psychiatry
- Pediatric Psychopharmacology
- Developmental Neurobiology of Aggression
- Disruptive Behavioral Disorders
- Depression
- Models of Clinical Service Delivery
- Case Assessment and Case Formulation in Child and Adolescent Psychiatry

REFERENCES

Available upon request